Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

Ki67 immunostaining has been performed on 136 primary breast cancers and related to various clinical and pathological features of the disease. Staining was most frequently seen in poorly differentiated tumours showing high rates of mitotic activity, but was independent of tumour size, lymph-node status and ER expression. A high level of Ki67 immunostaining was often associated with early recurrence of breast cancer after mastectomy. These data are consistent with the concept of the Ki67 antibody detecting an antigen that is closely related to cell proliferation and thus provides a clinically useful marker for this important characteristic of the tumour.

[1]  R. Silvestrini,et al.  Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics , 1974, Cancer.

[2]  L. V. van Putten,et al.  Proliferation-dependent cytotoxicity of anticancer agents: a review. , 1975, Cancer research.

[3]  J. Meyer,et al.  Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. , 1980, Cancer research.

[4]  M. Tubiana,et al.  Kinetic parameters and the course of the disease in breast cancer , 1981, Cancer.

[5]  R. Blamey,et al.  A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.

[6]  K. Goerttler,et al.  The proliferative index (PI) of human breast cancer as obtained by flow cytometry. , 1984, Pathology, research and practice.

[7]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[8]  M. Williams,et al.  Biological and clinical aspects of oestrogen receptor measurements in rapidly progressing breast cancer , 1984 .

[9]  H Stein,et al.  Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. , 1986, Journal of clinical pathology.

[10]  N. Lemoine,et al.  Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables , 1987, The Journal of pathology.

[11]  W Heidenreich,et al.  The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma , 1987, Cancer.